[Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
Sørensen
Soelberg
S
Sclerose Forskningsenheden, Københavns MS Center, Neurologisk Afdeling 2082, H:S Rigshospitalet. pss@rh.dk
Koch-Henriksen
Nils J
NJ
Pedersen
Christian Ross
CR
Clemmesen
Katja Maria
KM
Bendtzen
Klaus
K
Frederiksen
Jette Lautrup
JL
Jensen
Kai
K
Kristensen
Ole
O
Petersen
Thor
T
Rasmussen
Søren
S
Ravnborg
Mads
M
Stenager
Egon
E
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000276:immunology*; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000276:immunology*; D009500:Neutralization Tests; D011446:Prospective Studies
D000276:Adjuvants, Immunologic; D000906:Antibodies; D016899:Interferon-beta